c-myc protooncogene positively regulates cell proliferation and overexpression of c-myc is found in many solid tumors and leukemias. In the present study we used the K562 human myeloid leukemia cell line as a model to study the functional interaction between c-Myc and p53. Using two dierent methods, we generated K562 transfectant cell lines with conditional expression of either c-Myc or p53. The cells expressed the p53 Vall35 mutant, which adopts a wild-type conformation at 328C, while c-Myc induction was achieved with a zinc-inducible expression vector. We found that p53 in wild-type conformation induces growth arrest and apoptosis of K562. Expression of c-Myc signi®cantly attenuated apoptosis and impaired the transcriptional activity of p53 on p21 WAF1 , Bax and cytomegalovirus promoters. The impairment of p21 WAF1 transactivation by c-Myc was con®rmed by transfection of a c-Myc-estrogen receptor fusion protein and by induction of c-myc by zinc in transfected cells. Also, p53-mediated up-regulation of p21 WAF1 mRNA protein were signi®cantly reduced by cMyc, while Bax levels were unaected. Consistently, cMyc increased cyclin-dependent kinase 2 activity in K562 cells expressing p53 in wild-type conformation. These results suggest that c-Myc overexpression may antagonize the pro-apoptotic function of p53, thus providing a molecular mechanism for the frequently observed deregulation of c-myc in human cancer.
Introduction p53 is a transcription factor which is activated upon DNA damage and promotes cell growth arrest and apoptosis (Gottlieb and Oren, 1996; Ko and Prives, 1996; Levine, 1997) . Mutations and deletions of the p53 tumor suppressor gene is a common alteration in human cancer. In many neoplasias, and particularly those of hematopoietic origin, loss of normal p53 function occur during tumor progression, and tumors without wild-type p53 are more aggressive and have worse prognosis (Wallace-Brodeur and Lowe, 1999; Kirsch and Kastan, 1999) . Under genotoxic stress, p53 binds to speci®c DNA sequences and activates transcription of dierent genes. Some p53 target genes are involved in apoptosis control, e.g. bax, fas, and IGF-BP3, while others mediate cell cycle arrest, e.g. cyclin G, gadd45, 14-3-3s and the cyclin-dependent kinase inhibitor p21 WAF1 . However, the mechanisms by which p53 induces apoptosis are not completely understood (Hansen and Oren, 1997; Amundson et al., 1998; Bates and Vousden, 1999) .
c-Myc is a transcription factor involved in the control of cell proliferation, dierentiation and apoptosis. Mitogenic stimulation induces c-myc expression whereas growth arrest is usually accompanied by suppression of c-myc (Henriksson and LuÈ scher, 1996; Amati et al., 1998; Bouchard et al., 1998) c-Myc heterodimerizes with the protein Max and the dimer binds to regulatory regions of target genes. These include genes involved in cell cycle control and DNA and RNA metabolism (Grandori and Eisenman, 1997; Dang 1999) . Consistent with its positive eect on cell growth, deregulated expression of c-myc is a common ®nding in human cancer (Garte, 1993; Henriksson and LuÈ scher, 1996) . Paradoxically, c-Myc overexpression also mediates apoptosis in dierent cell types subjected to sub-optimal growth conditions, e.g. deprivation of growth factors or hypoxia (for recent reviews see Homan and Lieberman, 1998; Hueber and Evan, 1998; Thompson, 1998) . c-Mycmediated apoptosis requires wild-type p53 in ®broblasts (Hermeking and Eick, 1994; Wagner et al., 1994; Rupnow et al., 1998) , although there are examples where the apoptosis induced by c-Myc is p53-independent (Selvakumaran et al., 1994; Hsu et al., 1995; Sakamuro et al., 1995; Trudel et al., 1997; StaÈ hler and Roemer 1998; Hagiyama et al., 1999) . Besides, there are other data revealing a functional interaction between cMyc and p53: (i) wild-type p53 represses c-myc promoter (Moberg et al., 1992; Ragimov et al., 1993) and mutated p53 activates c-myc promoter (Frazier et al. 1998) ; (ii) cMyc induces p53 expression (Hermeking and Eick, 1994; Reisman et al., 1993; Roy et al., 1994; Kirch et al., 1999) (iii) c-myc and loss of wild-type of p53 function cooperate in the development of leukemia and lymphoma (Blyth et al., 1995; Lotem and Sachs, 1995; Eischen et al., 1999) . They also cooperate in the transformation of mouse ®broblasts (Taylor et al., 1992) , the immortalization of hematopoietic precursor cells (Metz et al., 1995) and the promotion of genomic instability (Yin et al., 1999) .
Chronic myeloid leukemia (CML) is usually diagnosed in a benign chronic phase, characterized by a clonal granulocytosis. The chronic phase lasts 1 ± 3 years and progresses to a fatal blast crisis. The molecular hallmark of all CMLs is the expression of the Bcr-Abl kinase, a fusion protein arising from a translocation (Melo, 1996) . The disease evolution suggests that secondary gene alterations are required for progression from chronic CML phase to blast crisis, but there is no evidence, to date, that a single molecular change is responsible for this progression. Alterations of p53 are very rare in the chronic phase of CML, and they occur with frequencies ranging 10 ± 25% of the blast crisis cases (Ahuja et al., 1991; Prokocimer and Rotter, 1994; Nakai and Misawas, 1995; Stuppia et al., 1997) although this frequency may be much lower, depending on the population analysed (Peller et al., 1998) . Interestingly, c-myc expression is higher in cells derived from blast crisis CML than from the chronic phase (Preisler et al., 1990; Handa et al., 1997) , and recent reports indicate a positive correlation of c-myc ampli®cation with progression to blast crisis (Beck et al., 1998; Jennings and Mills, 1998) . Moreover, the presence of an extra allele of c-myc (chromosome 8 trisomy) is the most common karyotypic alteration in CML blast crisis (46% of cases) (Alimena et al., 1987) .
K562 cells derive from CML in blast crisis and are de®cient in p53, due to the deletion of one allele and a frameshift mutation in the other (Bi et al., 1993; Law et al., 1993) . We have used the K562 system to study the role of c-Myc on p53 function. We show here that cMyc counteracts the apoptosis mediated by wild-type p53 and the up-regulation of p21 WAF1 expression.
Results

Wild-type p53 induces apoptosis in K562 cells
Kp53A1 cells are K562 transfected with a p53
Vall35 mutant, which were fully characterized previously (Ehinger et al., 1997) . This protein adopts a wild-type conformation at 328C, whereas it behaves like mutated p53 at 378C (Michalovitz et al., 1990; Milner and Medcalf, 1990) . As described (Law et al., 1993) , no p53 was detected by immunoblot in parental K562 cells, but signi®cant amounts of p53 protein were detected at 37 and 328C in Kp53A1 and Kp53C1 cells (Figure 1a) . To con®rm the presence of p53 in wild-type conformation at 328C we analysed the expression of bax and p21
WAF1
, two well-known transcriptional targets of p53. Upon transfer to 328C, the mRNA expression of both genes was clearly induced in Kp53A1, but not in parental K562 (Figure 1b) or vector-transfected KCMV cells (not shown). These results demonstrate that p53 is transcriptionally active at 328C in Kp53A1. Transfer of cells of 328C resulted in growth arrest, predominantly in G 1 phase (not shown), as well as progressive decrease in cell viability and appearance of apoptotic cells. The morphological analysis of cells revealed a dramatic increase of cells showing typical features of apoptosis: membrane bebbling, cell shrinkage, chromatin condensation and fragmentation and formation of apoptotic bodies (Figure 1c ). Similar result was observed for Kp53C1 cells (not shown). The apoptotic nature of Kp53A1 cell death at 328C was also con®rmed by the internucleosomal fragmentation of genomic DNA (Figure 1d) . At 328C the cells also exhibited other markers of apoptosis such as abnormal chromatin condensation revealed by DAPI staining and annexin V binding to the cell surface (see below). Thus, cell death induced by p53
Vall35 at 328C in K562 cells had the properties of typical apoptosis. This apoptosis showed a slow kinetics, as few apoptotic cells were detected after 24 h at 328C.
Construction of transfectant cell lines with conditional expression of c-Myc and p53 in wild-type conformation
To study the eect of c-Myc on p53-mediated apoptosis of K562 we generated double transfectants with conditional expression of p53 in the wild-type conformation and c-Myc. Kp53A1 cells were transfected with pHeBO-MT-myc, a zinc-inducible c-Myc expression vector (Grignani et al., 1990) . Individual clones resistant to G418 (as Kp53A1 cells) and hygromycin (transfected with c-myc) were isolated. One cell clone was selected for further experiments and termed Kp53A1/myc. The construction of this line and its expected expression pattern is schematized in Figure  2a . The expression of ectopic c-myc mRNA is markedly induced after 24 h of treatment with 75 mM ZnSO 4 (Figure 2b ). The transfected gene lacks the ®rst non-coding c-myc exon and therefore it produces a smaller mRNA than the endogenous gene (Grignani et al., 1990) . Kp53A1/myc cells also overexpressed c-Myc protein after zinc addition, as shown by immunoblot (Figure 2c ). To rule out the possibility that the results were due to the particular cell clone selected, we generated another double transfectant cell line by the inverse pathway to that followed to generate Kp53A1/ myc cells. Thus, we infected KmycB cells (with zincinducible expression of c-myc) (Delgado et al., 1995) , with a retrovirus expressing the p53
Vall35 mutant. Cells resistant to hygromycin (as KmycB cells) and puromycin (infected with the p53 retroviral vector) were selected and dubbed KmycB/p53 (Figure 2a 
c-Myc protects K562 cells from p53-mediated apoptosis
We then analysed the eect of c-Myc induction on p53-mediated apoptosis. As shown in Figure 3a , when cells were shifted to 328C in the presence of 75 mM ZnSO 4 , the loss in cell viability was attenuated. Likewise, the fraction of cells with apoptotic morphology was signi®cantly reduced in the presence of 75 mM ZnSO 4 (60 versus 20% apoptotic cells after 4 days with zinc). No signi®cant changes in cell morphology were observed in those cells not undergoing apoptosis in the zinc-treated cultures (not shown). The extent of apoptosis protection was similar for Kp53A1/myc and KmycB/p53 cell lines (Figure 3a) . No changes in viability were detected among the dierent cell lines when the experiments were performed at 378C (not shown). The abrogation of apoptosis mediated by cMyc was also demonstrated by determining the metabolic rate, using the WST-1 tetrazolium salt reduction test (not shown). Altogether, the results con®rmed that c-Myc overexpression protects K562 cells from p53-mediated apoptosis. However, the induction of c-Myc at 328C (i.e., with p53 in wild-type conformation) in Kp53A1/myc and KmycB/p53 cells did not restore full growth ability, and did not change the cell cycle phase distribution. Cell counts in the presence of zinc increased about twofold after 24 h at 328C but did not grow further, and no changes were detected in the extent of G1 arrest with respect to untreated cells (not shown). The protection from apoptosis by c-Myc was also determined by the translocation of phosphatidylserine to the outer layer of cell membranes, as determined by annexin V binding. Our results showed that the shift-down to 328C resulted in a dramatic increase in the number of cells positive for annexin V. However, the presence of 75 mM ZnSO 4 resulted in a decrease of about 50% in the fraction of Kp53A1/myc and KmycB/p53 cells bound to annexin ( Figure 3b ).
Next we analysed the eect of c-Myc on p53-mediated apoptosis by determining the internucleosomal DNA fragmentation. DNA laddering was clearly reduced in both Kp53A1/myc and KmycB/p53 cell lines incubated at 328C for 72 h in the presence of 75 mM ZnSO 4 , with respect to cells incubated without zinc (Figure 3c ). In contrast, extensive DNA fragmentation was observed in Kp53A1 cells either in the presence or absence of ZnSO 4 . We also determined the eect of c-Myc expression on apoptosis by analysing the extent of chromatin condensation by DAPI staining. KmycB/p53 and Kp53A1/myc cells were incubated for 72 h at 328C in the presence or absence of 75 mM ZnSO 4 , and the fraction of apoptotic cells was dramatically reduced in zinc-treated cells ( Figure  3d ). We conclude that c-Myc inhibits the apoptosis mediated by wild-type p53 in K562. As p53 may be expressed at dierent levels among individual cells, it is formally possible that c-Myc overexpression allows the growth of those cells with lower p53 expression. Thus, a population of p53-negative and apoptosis-resistant cells could be selected during zinc treatment at 328C of Kp53A1/myc or KmycB/p53 cells. However, the expression of p53, as assessed by immunoblot, did not decrease signi®cantly after 96 h at 328C in the presence of zinc (not shown). Also, p53 is detected by immuno¯uorescence in the nuclei of Kp53A1/myc cells incubated at 328C in the presence of zinc (not shown), ruling out a c-Myc-mediated impairment of p53 translocation to the nucleus.
c-Myc antagonizes the transcriptional activities of p53 in K562
To investigate possible mechanisms by which c-Myc could exert its protective eect on p53-mediated apoptosis, we studied the transactivation activity of p53 on the promoters of bax and p21
WAF1
, two p53 target genes involved in apoptosis and cell cycle arrest. We ®rst con®rmed that co-transfection of wild-type p53 expression vector (pLPC-hp53) into the parental K562 cells resulted in a dramatic activation of the p21 WAF1 promoter (58-fold, mean of four experiments). The induction was similar at 328C and 378C (not shown). The eect of c-Myc on p53-dependent transcription was studied by transfecting into K562, pLPC-hp53 with and without an expression vector encoding c-Myc (LMycSN), together with the p53-responsive bax, mdmd2 and p21 WAF1 promoter-luciferase reporters. Interestingly, c-Myc reduced the transactivation of the three promoters by 40 ± 60% depending on the promoter analysed ( Figure 4a ). We also tested whether c-Myc impaired the p53-mediated transcriptional repression of cytomegalovirus (CMV) immediate early promoter (Subler et al., 1992; Jackson et al., 1993) . The results showed that this repression was clearly attenuated by co-expression of c-Myc ( Figure  4a) .
We investigated the c-Myc eect in Kp53A1 and Kp53C1 cells. First, we con®rmed that the shift to 328C of Kp53A1 cells resulted in a notable increase in the activity of p21 WAF1 promoter, in agreement with the presence of p53 in wild-type conformation (Figure 4b ). This increase was abolished by co-transfection of the papilloma virus E6 gene expression vector (Figure 4b ), or by deleting the p53-responsive elements of the p21 WAF1 promoter (not shown), demonstrating that p53 was responsible for this transactivation. Next, Kp53A1 and Kp53C1 cells were co-transfected with the dierent reporters together with a c-Myc expression vector (LMycSN) and incubated at 32 and 378C. Transcriptional activation of bax and p21 WAF1 promoters was dramatically induced at 328C (Figure 4c ), but it was reduced by 40 ± 60% upon co-transfection of c-Myc expression vector. Likewise, p53-mediated repression of CMV promoter was reduced by c-Myc expression (Figure 4c) . Thus, c-Myc impaired both the transcriptional activation and repression activities of p53 in the K562 model. In contrast, the p53-independent upregulation of p21 WAF1 induced by phorbol esters or okadaic acid in K562 (Zeng and El-Deiry, 1996) was As p21 WAF1 transactivation correlated to the changes at protein level (see below), we sought to con®rm the c-Myc eect on p53-induced transactivation of p21 WAF1 promoter by three approaches. First, we transfected the p21 WAF1 -luciferase construct along with increasing amounts of c-myc expression vector (6, 10 and 14 mg of LMycSN) into Kp53A1. The results revealed an increased blocking eect of the p53-induced transactivation of p21 WAF1 with higher c-myc doses. With the highest amount of transfected c-myc expression, the activity of p21 WAF1 promoter fell to 20% of control activity ( Figure  5a ). Second, we transfected the p21 WAF1 -luciferase reporter, along with an expression vector for cMycER TM . This is a fusion protein of c-Myc and a mutant hormone binding site of estrogen receptor. The cMyc activity of this protein is activated upon addition of 4-hydroxytamoxifen (Littlewood et al., 1995) . The results indicated that p21 WAF1 promoter activity was reduced by 4-hydroxytamoxifen in a concentrationdependent manner, reaching 60% of inhibition in cells treated with 500 nM 4-hydroxytamoxifen (Figure 5b) . No eect of the hormone on promoter activity was detected in cells transfected with the empty vector.
Finally, we tested p21 WAF1 promoter activity in Kp53A1/myc or KmycB/p53 cells at 328C in the absence and presence of zinc, i.e., under conditions in which c-Myc induction was concomitant with apoptosis protection. When the cells were shifted to 328C, the expression of luciferase was induced by about 10-fold ( Figure 5c , white bars), in accordance with the change to a wild-type conformation of p53. When the experiment was conducted in the presence of zinc the activity of the p21 WAF1 promoter was reduced by 40% compared to the cells without zinc (Figure 5c ). Essentially, the same results were obtained with KmycB/p53 and Kp53A1/myc cells. The reduction in p21 WAF1 promoter activity upon zinc addition was reproduced in 10 independent experiments among the two cell lines. Similar results were observed with 75 and 100 mM ZnSO 4 (not shown). Zinc addition also reduced the activity of Bax promoter in these cell lines (not shown). As expected, zinc addition did not decrease p53-mediated p21 WAF1 transactivation of Kp53A1 cells shifted to 328C (Figure 5c ) or K562 transfected with a wild-type p53 expression vector (not shown). To assess that zinc induced active c-Myc, we used a luciferase reporter carrying a Myc-responsive promoter (pGL2M4-Luc). The results con®rmed that c-Myc transcriptional activity is elevated when protecting cells from apoptosis (Figure 5c ).
c-Myc antagonizes the up-regulation of p21
WAF1 mediated by p53 in K562
We investigated the levels of mRNA and protein of Bax, Mdm2 and p21
WAF1
in Kp53A1/myc and KmycB/p53 cells. As expected from the presence of p53 in wild-type conformation, the shift to 328C resulted in the induction of bax and p21 WAF1 mRNA expression (Figure 6a , lanes 4 ± 7). After addition of 75 mM ZnSO 4 a dramatic induction of exogenous cmyc mRNA was observed. The endogenous c-myc expression declined at 328C, in consistency with the reported eect of mutant and wild-type p53. When cMyc expression was induced by zinc addition, no signi®cant changes in bax mRNA levels ( Figure 6a ) and protein (not shown) were observed. In contrast, levels of p21 WAF1 mRNA were clearly decreased in both cell lines after 24 h of incubation at 328C in the presence of zinc (Figure 6a , lanes 4 and 7) compared to parallel cultures without zinc (Figure 6a , lanes 5 and 6). The eect of c-Myc on mRNA was also observed at the level of p21 WAF1 protein, as shown by immunoblot (Figure 6b ). The correlation between p21 WAF1 protein down-regulation and inhibition of cyclin-dependent kinase 2 (CDK2) was studied in Kp53A1/myc and KmycB/p53 cells in the presence and absence of c-Myc induction. The result showed that incubation of the cells at 328C caused a marked repression of CDK2 activity and that c-Myc counteracted this repression. This result was obtained assaying both the CDK2-and the cyclin E-associated kinase activity (Figure 6c) . Altogether, our results show that c-Myc impairs the induction of p21 WAF1 expression mediated by wild-type p53 in K562 cells and that this eect occurs at the transcriptional level.
Discussion
The present study provides evidence that c-Myc antagonizes both the apoptosis and the up-regulation of p21 WAF1 mediated by p53. Using the p53 Val135 mutant we ®rst showed that p53 in wild-type form induces growth arrest followed by cell death of K562. The cell death induced by wild-type p53 in K562 transfectants has the morphological and biochemical features of typical apoptosis. p53-induced K562 cell death has been reported (Kremenetskaya et al., 1997; Trepel et al., 1997) . In contrast, other studies indicate that K562 expressing wild-type p53 are able to grow, albeit at a slower rate and accompanied by erythroid dierentiation (Ehinger et al., 1995; Feinsten et al., 1992) . The most obvious explanation for these dierences is that higher levels of p53 in wild-type conformation are easier to obtain in stable transfectants with a termosensitive mutant, since the transfection with constitutive wild-type p53 will select against those cell clones overexpressing the pro-apoptotic protein. WAF1 (`p21-Luc') or cytomegalovirus (`CMV-Luc') promoters, and 9 mg of pLPCX, pLPC-hp53, LXSN or LMycSN.`Vectors' refers to cells transfected with the two empty vectors. Luciferase activity was determined as described in Materials and methods. (b) Kp53A1 cells were transfected with 3 mg of pGL3-basic vector (`pGL3'), p21-Luc reporter and p21-Luc with a papillomavirus E6 gene expression vector (CMV16-E6,`E6'). (c) Kp53A1 and Kp53C1 cells were transfected with the reporter plasmids as indicated above for K562 and co-transfected with 9 mg of LXSN or LMycSN. Fourteen hours after transfection, aliquots of the culture were incubated at 37 or 328C for 24 h and the luciferase activity of cell lysates was determined. Several transfections with similar results were performed for each plasmid combination, and representative results are shown. The maximum luciferase activity value was set at 100% for each reporter and the other data were normalized to this value Interestingly, ectopic expression of c-Myc counteracts the apoptosis induced by wild-type p53 in K562 cells. This result seems paradoxical as c-Myc induce apoptosis in dierent cell types under conditions of growth factor deprivation. However, c-Myc overexpression induces little apoptosis of K562 cells in the absence of serum (CanÄ elles et al., 1997) . This is consistent with the lack of expression of p53 (Law et al., 1993) , p19 ARF (Delgado et al., 2000) and CD95/ FAS (McGahon et al., 1995) in K562, as the three proteins are required for c-Myc-mediated apoptosis in ®broblasts (Hermeking and Eick, 1994; Hueber et al., 1997; Wagner et al., 1994; Zindy et al., 1998) . However, c-Myc does not confer an unspeci®c antiapoptotic eect on K562 cells, as it does not protect from other apoptotic stimuli as okadaic acid or ceramides (CanÄ elles et al., 1997; our unpublished results). The antiapoptotic eect of c-Myc has also been described in lymphoid cells (Sonenshein, 1997; Felsher and Bishop, 1999) and keratinocytes (Waikel et al., 1999) , but its relationship with p53 function in these processes is unknown.
How does c-Myc impair the p53-mediated apoptosis in K562 cells? One obvious possibility is that cMyc abrogates the transcriptional activation of p53 target genes. We tested bax and p21 WAF1 genes, and the p53-mediated transactivation of both promoters was attenuated by c-Myc overexpression. Moreover, c-Myc attenuates the p53-mediated repression of CMV immediate early promoter. Thus c-Myc interferes with both the transcriptional activation and repression mediated by p53. Bax mRNA and protein levels were unchanged by c-Myc expression, ruling out the Bax down-regulation as a mechanism for apoptosis protection. In contrast, the expression of p21 WAF1 mRNA and protein was dramatically reduced. Inhibition of p53-dependent induction of p21 WAF1 is a newly described activity of c-Myc. In NIH3T3 ®broblasts the ectopic expression of c-Myc abrogates the p21 WAF1 inhibitory activity on cyclin dependent kinases but it does not modify its expression (Hermeking et al., 1995) . During the preparation of this manuscript, it has been reported that c-Myc inhibits phorbol ester-induced p21 WAF1 up-regulation in prostate and breast cancer cell lines (Mitchell and El-Deiry, 1999) . Thus, c-Myc-mediated inhibition of p21 WAF1 transactivation described herein for K562 may occur widely among tumor cells. Other recent studies show that loss of c-Myc in rat Rat-1 cells results in a reduction of p21 WAF1 (Mateyak et al., 1999) . This reinforces the idea that c-Myc does not directly interact with p21 WAF1 or Bax promoters and that the eect on p53 transcriptional activity depends on the cell type. TM or the empty vector (pBabePuro) along with the reporter plasmid. After 14 h at 378C, the culture was divided into four aliquots and incubated for 24 h at 32 or 378C in the presence of 0, 50, 100 and 500 nM 4-hydroxytamoxifen (from open to solid histograms) before determination of luciferase activity. Bars indicate the standard deviation from the mean of three independent experiments. (c) Eect of c-Myc in Kp53A1/myc, KmycB/p53 and Kp53A1. Cells were transfected with 3 mg pGL3-Waf1-Luc (`p21-Luc') and 9 mg of pLPCX (as carrier DNA) and incubated at 37 or 328C in the presence or absence of 100 mM ZnSO 4 (`Zn'). Right panel show the transactivation of a Myc-responsive luciferase reporter (pGL2M4-Luc,`M4-Luc') in the presence and absence of 100 mM ZnSO 4 Does the c-Myc-mediated down-regulation of p21 WAF1 explain the abrogation of p53-dependent apoptosis?. Given that the mechanism of p53-induced apoptosis is not well understood, we can only speculate on the possible mechanisms that are responsible for c-Myc-mediated supression of apoptosis. p21 WAF1 appears to be necessary for growth arrest but not for apoptosis induced by wild-type p53 (Bates and Vousden, 1999; Hansen and Oren, 1997) . It is formally possible that p21 WAF1 accumulation eventually results in apoptosis of K562 cells, as has already been described in other systems as neuroblastoma (Poluha et al., 1996) , lung carcinoma (Adachi et al., 1996) , breast carcinoma (Sheikh et al., 1995) , colon carcinoma (Chinery et al., 1997; Polyak et al., 1996) , and lymphoid cells (Wu et al., 1998) . However, it has been reported that expression of another p53 mutant (p53
Val143
) in K562 results in p21 WAF1 up-regulation without concomitant apoptosis (Kobayashi et al., 1995) . Also, co-transfection of an antisense-p21 WAF1 expression vector did not alleviate the apoptosis due to p53 in K562 (our unpublished results). Thus it seems unlikely that p21 WAF1 decline by itself is responsible for the protective eect of cMyc. Our results rather indicate that c-Myc interferes with the ability of p53 to act as transcription factor in K562, as it not only antagonizes the activation of Bax and p21 WAF1 promoters but also the repression of CMV promoter. It must be noted that there might be many p53-target genes involved in apoptosis, and therefore it is possible that c-Myc interferes with p53-dependent induction of other pro-apoptotic proteins.
Independently of the mechanisms involved, our results oer a new clue for the role of c-Myc in the development of leukemia. On one hand, c-myc overexpression has been implicated in the malignant progression of human tumors (Garte, 1993; Henriksson and LuÈ scher, 1996; Berns et al., 1992) . On the other hand, apoptosis is a well-documented consequence of c-Myc ectopic expression in cells subjected to growth factor deprivation or to hypoxia. Moreover, a correlation between high c-myc expression and apoptosis has been reported for some solid tumors (Homan and Liebermann, 1998; Alarcon et al., 1996; Donzelli et al., 1999) . However, the pro-apoptotic eect of c-Myc is at odds with the frequently found cmyc overexpression in human cancer. This is most intriguing in those tumors retaining p53 function, which occurs in a majority of the cases in some hematological neoplasias, e.g. CML blast crisis (Ahuja et al., 1991; Prokocimer and Rotter 1994; Nakai and Misawa, 1995; Stuppia et al., 1997) , Burkitt lymphomas (Newcomb, 1995) and mouse plasmacytomas (Gutierrez et al., 1992) . Thus, c-Myc overexpression must confer some selective advantage which counteracts its apoptotic eect. It has been suggested that tumors produce survival factors able to block the apoptotic eect of c-Myc, leaving the proliferative pathway unrestrained. Although our data do not contradict this hypothesis, they indicate that, at least in some tumors, an additional mechanism may be The extracts were immunoprecipitated with anti-CDK2 or anti-cyclin E antibodies as indicated and the kinase activity of the immune complexes was determined using histone H1 as substrate operating which can explain c-myc overexpression during tumor progression. Given the fact that p53 plays a pivotal role in mediating drug-or radiationinduced apoptosis, we propose that c-Myc overexpression could protect tumor cells from apoptosis mediated by p53.
Materials and methods
Cell lines, transfection and retroviral transduction
All cell lines were grown in RPMI 1640 medium (Gibco-Life Sciences) supplemented with 8% fetal calf serum and gentamycin (80 mg/ml). Kp53A1 cells (originally termed K562/ptsp53/A1) are K562 cells expressing a mouse p53
Val 135 mutant (Ehinger et al., 1997) . The KCMV cell lines are K562 transfected with neo-resistant vector (Ehinger et al., 1997) . KmycB are K562 cells transfected with a zincinducible c-myc gene (Delgado et al., 1995) . Kp53C1 cells were generated by infecting K562 cells with retrovirus containing the vector pBabePuro-p53
Val135 (provided by M Oren, Weizmann Institute, Revohot, Israel). The vector was electroporated into Phoenix-A cells and the supernatant used to infect K562 cells in the presence of 6 mg/ml polybrene. Infected cells were selected with 2 mg/ml puromycin and the resulting culture of puromycin-resistant cells was termed Kp53C1. To generate the Kp53A1/myc cell line, Kp53A1 cells were electroporated at 260 v and 1 mFa with pHeBO-MT-myc vector which carries a c-myc gene under the control of metallothionein promoter (Grignani et al., 1990) . Cells and selected with 0.5 mg/ml of G418 and 0.1 mg/ml of hygromycin. Cell clones were isolated by limiting dilution. KmycB/ p53 cells were generated by infecting KmycB cells with pBabePuro-p53
Val135 retroviruses as described above. The p53 transfectant cell lines tended to lose the apoptotic phenotype after prolonged cell culture, and fresh stocks were used for most experiments.
Apoptosis determinations
When indicated, exponentially growing cells at a concentration of 2610 5 cells/ml were transferred to 328C. Cell morphology was analysed by May-GruÈ nwald-Giemsa or 4,6-diamino-2-phenylindole (DAPI) staining of cytocentrifuge preparations. At least 200 cells were scored for each determination of apoptotic or metaphasic cells. Cell growth and viability were assayed with hemocytometer and the trypan blue exclusion test and by colorimetry based on the reduction of the tetrazolium salt WST-1 (Roche Molecular Biochemicals). To determine the presence on internucleosomal fragmentation (DNA laddering), cellular DNA was prepared and analysed by agarose gel electrophoresis as described (CanÄ elles et al., 1997) . Binding of annexin V to cell surface was carried out by¯ow cytometry with annexin V-FITC kit following the manufacturer's instructions (Genzyme Diagnostics).
RNA, protein and kinase activity analysis
Total RNA was isolated from cells by the acid guanidine thiocyanate method and Northern blots were prepared and hybridized according to standard procedures. Probe for human c-myc was as described (Delgado et al., 1995) ; for p53, a 2.1 kb XhoI ± BamHI fragment from pLTRp53cG corresponding to mouse cDNA (provided by M Oren); for p21 WAF1 a 0.6 kb NotI fragment from pBSK-p21 corresponding to human cDNA (provided by M Serrano, Centro Nacional de BiotecnologõÂ a, Madrid); for bax, a 0.5 kb EcoRI fragment form pSSFV-Bax corresponding to human cDNA (provided by S Korsmeyer, Washington University Medical School, St. Louis, USA). For immunoblots, cell lysates were prepared and immunoblotted as described (CanÄ elles et al., 1997) . c-Myc and p21
WAF1
were detected with rabbit polyclonal antibodies, p53 with the monoclonal antibody PAb240 (Santa Cruz Biotech.), and a-tubulin with a rabbit polyclonal antibody (provided by N Cowan, New York University, NY, USA). Immunocomplexes were detected with peroxidase-conjugated secondary antibodies (Cappel) and chemiluminescent method (ECL, Amersham). For kinase assays, cyclin E and CDK2 immunoprecipitations were performed essentially as described (Mateyak et al., 1999) , using anti-cyclin E (M-20, Santa Cruz) and anti-CDK2 (M2, Santa Cruz) antibodies. Kinase activity of the immunoprecipitates was assayed using histone H1 as substrate.
Transactivation assays
Cells were transfected by electroporation at 260 v and 1 mFa in a Bio-Rad electroporator. Cells (4 ± 8610 6 ) were cotransfected with the appropriate plasmids and after 14 h of incubation at 378C, cultures were split into aliquots and further incubated for 24 h at 32 or 378C in the absence or presence of 100 mM ZnSO 4 or 50 ± 500 nM 4-hydroxytamoxifen. Cells were lysed and the luciferase activity was measured by a dual-luciferase reporter gene assay system (Promega). Plasmids used were: pGL3-Waf1-Luc (provided by M Oren) which contains a 2.3-kb of p21 WAF1 promoter upstream of the ®re¯y luciferase cDNA, pGL3-Bax-Luc (provided by M Oren), CMV-Luc (Bellon et al., 1994) , pLPC-hp53 vector expressing wild-type p53 (provided by M Serrano) and its corresponding empty vector pLPCX (Serrano et al., 1997) ; pGL2M4-Luc (provided by R Eisenman, Fred Hutchinson Cancer Research Center, Seattle, USA), LMycSN (provided by R Eisenman) and the empty vector LXSN (Miller et al., 1993) , pCMV16-E6 which carries the human papilloma virus E6 gene (provided by K Cho, Johns Hopkins University, Baltimore, USA), and pBpuro-c-mycER TM (provided by T Littlewood, Imperial Cancer Research Fund, London, UK) and the vector pBabePuro (Littlewood et al., 1995) . In each transfection experiment, the same amount of total DNA was transfected for all samples, using the empty vectors as carrier DNA. One mg of the pRL-TK plasmid encoding for Renilla luciferase (Promega) was co-transfected in each case. Promoter activity was de®ned as the ratio between light units generated by the ®re¯y and Renilla luciferases.
